Table 1.

Patient characteristics.

Characteristic	(n = 76)
Male gender–no. (%)	39 (51%)
Age–year
Median	60
Range	30–84
WHO performance status–no. (%)
0	43 (57%)
1	33 (43%)
Previous CT line
Median	2
Range	1–7
Primary tumor resected–no. (%)	63 (83%)
Number of metastatic sites
Median	3
Range	1–10
Metastases–no. (%)
Peritoneum	20 (26%)
Liver	50 (66%)
Lung*	49 (65%)
Nodes	35 (46%)
Bone§	9 (12%)
Other§	18 (24%)
Molecular profile–no. (%)
KRAS mutation
Available in	71 (93%)
Mutated	44 (62%)
NRAS mutation
Available in	58 (76%)
Mutated	2 (3%)
BRAF mutation
Available in	68 (89%)
Mutated	3 (4%)
Her 2 amplification
Available in	30 (39%)
Mutated	6 (20%)
MSI
Available in	44 (58%)
Mutated	4 (9%)
OS–months
Median	5
Range	1–52
PFS–weeks
Median	10
Range	3–52
Alive–no. (%)	19 (25%)

^*75 observations;

^§74 observations.